Free Trial
→ The Coin That Could Define Trump’s Crypto Presidency (From Weiss Ratings) (Ad) Free CLDX Stock Alerts

Celldex Therapeutics (CLDX) Financials

Celldex Therapeutics logo
$20.66 -0.55 (-2.59%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$20.68 +0.02 (+0.10%)
As of 08/8/2025 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Celldex Therapeutics

Annual Income Statements for Celldex Therapeutics

This table shows Celldex Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -118 -127 -129 -93 -151 -51 -60 -71 -112 -141 -158
Consolidated Net Income / (Loss)		 -118 -127 -129 -93 -151 -51 -60 -71 -112 -141 -158
Net Income / (Loss) Continuing Operations		 -118 -127 -129 -93 -151 -51 -60 -71 -112 -141 -158
Total Pre-Tax Income 		-118 -127 -129 -117 -152 -51 -61 -71 -112 -141 -158
Total Operating Income		 -122 -130 -133 -122 -156 -55 -63 -71 -115 -155 -195
Total Gross Profit		 3.59 5.48 6.79 13 9.54 3.57 7.42 4.65 2.36 6.88 7.02
Total Revenue		 3.59 5.48 6.79 13 9.54 3.57 7.42 4.65 2.36 6.88 7.02
Operating Revenue		 3.59 5.48 6.79 13 9.54 3.57 7.42 4.65 2.36 6.88 7.02
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 126 135 140 134 166 59 71 76 118 161 202
Selling, General & Admin Expense		 21 34 36 25 19 15 14 20 27 31 39
Research & Development Expense		 104 100 103 96 66 43 43 53 82 118 164
Other Operating Expenses / (Income)		 - - - -0.80 -30 -1.29 -4.22 -1.41 -6.86 0.00 0.00
Other Special Charges / (Income)		 - - - - - - 0.00 0.00 15 13 0.00
Total Other Income / (Expense), net		 4.35 2.34 4.39 4.21 4.49 4.15 2.41 0.51 2.91 13 37
Interest & Investment Income		 4.35 2.34 4.39 4.21 4.49 4.15 2.41 0.51 2.91 13 37
Basic Earnings per Share		 ($1.32) ($1.31) ($18.99) ($10.86) ($14.48) ($3.51) ($2.02) ($1.64) ($2.40) ($2.92) ($2.45)
Weighted Average Basic Shares Outstanding		 89.40M 97.05M 6.77M 8.57M 10.44M 14.51M 29.64M 42.87M 46.89M 48.45M 64.40M
Diluted Earnings per Share		 ($1.32) ($1.31) ($18.99) ($10.86) ($14.48) ($3.51) ($2.02) ($1.64) ($2.40) ($2.92) ($2.45)
Weighted Average Diluted Shares Outstanding		 89.40M 97.05M 6.77M 8.57M 10.44M 14.51M 29.64M 42.87M 46.89M 48.45M 64.40M
Weighted Average Basic & Diluted Shares Outstanding		 89.40M 97.05M 6.77M 8.57M 10.44M 14.51M 29.64M 46.74M 47.21M 55.90M 66.38M

Quarterly Income Statements for Celldex Therapeutics

This table shows Celldex Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -27 -26 -29 -31 -38 -43 -33 -36 -42 -47 -54
Consolidated Net Income / (Loss)		 -27 -26 -29 -31 -38 -43 -33 -36 -42 -47 -54
Net Income / (Loss) Continuing Operations		 -27 -26 -29 -31 -38 -43 -33 -36 -42 -47 -54
Total Pre-Tax Income 		-27 -86 0.00 0.00 0.00 -141 -33 0.00 0.00 -158 -54
Total Operating Income		 -28 -28 -32 -33 -41 -48 -41 -46 -52 -56 -63
Total Gross Profit		 0.41 1.61 0.97 0.27 1.52 4.13 0.16 2.50 3.19 1.18 0.70
Total Revenue		 0.41 1.61 0.97 0.27 1.52 4.13 0.16 2.50 3.19 1.18 0.70
Operating Revenue		 0.41 1.61 0.97 0.27 1.52 4.13 0.16 2.50 3.19 1.18 0.70
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 28 29 33 33 43 52 41 49 55 57 63
Selling, General & Admin Expense		 6.53 6.60 6.64 7.22 8.22 8.83 9.10 9.13 10 10 11
Research & Development Expense		 22 23 27 26 35 30 32 40 45 47 53
Total Other Income / (Expense), net		 0.91 1.40 3.11 2.70 2.98 4.32 7.80 10 10 8.94 8.94
Interest & Investment Income		 0.91 1.40 3.11 2.70 2.98 4.32 7.80 10 10 8.94 8.94
Basic Earnings per Share		 ($0.57) ($0.57) ($0.62) ($0.65) ($0.81) ($0.84) ($0.56) ($0.54) ($0.64) ($0.71) ($0.81)
Weighted Average Basic Shares Outstanding		 46.92M 46.89M 47.21M 47.25M 47.26M 48.45M 58.87M 66.02M 66.29M 64.40M 66.38M
Diluted Earnings per Share		 ($0.57) ($0.57) ($0.62) ($0.65) ($0.81) ($0.84) ($0.56) ($0.54) ($0.64) ($0.71) ($0.81)
Weighted Average Diluted Shares Outstanding		 46.92M 46.89M 47.21M 47.25M 47.26M 48.45M 58.87M 66.02M 66.29M 64.40M 66.38M
Weighted Average Basic & Diluted Shares Outstanding		 47.10M 47.21M 47.25M 47.26M 47.26M 55.90M 65.91M 66.29M 66.34M 66.38M 66.39M

Annual Cash Flow Statements for Celldex Therapeutics

This table details how cash moves in and out of Celldex Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -141 44 -30 -2.17 -16 -13 33 -4.69 -9.71 5.39 -6.46
Net Cash From Operating Activities		 -102 -99 -113 -100 -75 -46 -40 -61 -104 -107 -158
Net Cash From Continuing Operating Activities		 -102 -99 -113 -100 -75 -46 -40 -61 -104 -107 -158
Net Income / (Loss) Continuing Operations		 -118 -127 -129 -93 -151 -51 -60 -71 -112 -141 -158
Consolidated Net Income / (Loss)		 -118 -127 -129 -93 -151 -51 -60 -71 -112 -141 -158
Depreciation Expense		 2.39 3.00 3.10 4.41 3.58 4.86 3.93 3.07 2.90 3.01 3.18
Amortization Expense		 1.18 1.65 3.56 1.19 -0.82 -1.14 -0.73 -3.21 0.84 -6.22 -16
Non-Cash Adjustments To Reconcile Net Income		 6.85 13 15 0.98 89 5.07 21 12 16 24 34
Changes in Operating Assets and Liabilities, net		 6.13 11 -6.56 -13 -15 -4.32 -4.52 -2.46 -11 13 -22
Net Cash From Investing Activities		 -41 -50 69 46 30 17 -98 -216 90 -106 -290
Net Cash From Continuing Investing Activities		 -41 -50 69 46 30 17 -98 -216 90 -106 -290
Purchase of Property, Plant & Equipment		 -1.93 -4.88 -2.75 -1.79 -0.81 -0.73 -1.55 -1.25 -1.83 -1.82 -1.92
Purchase of Investments		 -148 -206 -176 -171 -171 -95 -220 -390 -189 -425 -790
Sale of Property, Plant & Equipment		 - - - - 0.34 0.02 0.06 0.03 0.07 0.00 0.00
Sale and/or Maturity of Investments		 109 161 243 219 201 113 124 175 281 321 502
Other Investing Activities, net		 - - - - - - - -0.29 -0.11 -0.08 -0.03
Net Cash From Financing Activities		 1.17 193 14 51 29 16 171 272 4.08 218 441
Net Cash From Continuing Financing Activities		 1.17 193 14 51 29 16 171 272 4.08 218 441
Issuance of Common Equity		 1.17 193 14 51 29 16 171 272 4.08 218 441

Quarterly Cash Flow Statements for Celldex Therapeutics

This table details how cash moves in and out of Celldex Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -9.82 11 25 -26 -7.09 14 80 -72 -6.34 -8.04 -11
Net Cash From Operating Activities		 -35 -22 -29 -27 -19 -33 -41 -29 -55 -32 -54
Net Cash From Continuing Operating Activities		 -35 -22 -29 -27 -19 -33 -41 -29 -55 -32 -54
Net Income / (Loss) Continuing Operations		 -27 -26 -29 -31 -38 -43 -33 -36 -42 -47 -54
Consolidated Net Income / (Loss)		 -27 -26 -29 -31 -38 -43 -33 -36 -42 -47 -54
Depreciation Expense		 0.67 0.67 0.73 0.76 0.77 0.76 0.78 0.80 0.79 0.82 0.87
Amortization Expense		 0.06 -0.52 -1.26 -1.16 -1.63 -2.18 -3.31 -4.74 -4.33 -3.36 -2.27
Non-Cash Adjustments To Reconcile Net Income		 -11 4.51 4.34 5.22 7.12 7.21 7.21 7.64 9.62 9.78 9.32
Changes in Operating Assets and Liabilities, net		 1.42 0.07 -3.02 -1.51 13 4.98 -13 2.82 -19 7.38 -8.50
Net Cash From Investing Activities		 23 31 53 1.16 12 -171 -315 -47 48 24 43
Net Cash From Continuing Investing Activities		 23 31 52 1.25 11 -171 -315 -47 48 24 43
Purchase of Property, Plant & Equipment		 -0.35 -0.24 -0.59 -0.41 -0.16 -0.67 -0.34 -0.27 -0.55 -0.76 -0.27
Purchase of Investments		 -63 -56 -74 -82 -28 -241 -392 -169 -100 -129 -152
Sale and/or Maturity of Investments		 86 88 127 83 40 71 77 122 148 154 195
Net Cash From Financing Activities		 2.31 1.40 0.69 0.13 0.26 217 436 3.71 1.24 0.39 0.20
Net Cash From Continuing Financing Activities		 2.31 1.40 0.69 0.13 0.26 217 436 3.71 1.24 0.39 0.20
Issuance of Common Equity		 2.31 1.40 0.69 0.13 0.26 217 436 3.71 1.24 0.39 0.20

Annual Balance Sheets for Celldex Therapeutics

This table presents Celldex Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 248 338 383 316 156 123 236 445 353 466 792
Total Current Assets		 205 295 196 145 99 67 198 411 318 432 747
Cash & Equivalents		 28 72 42 40 24 11 44 39 29 35 28
Short-Term Investments		 173 218 147 99 70 53 151 369 276 389 697
Accounts Receivable		 0.43 0.97 1.78 1.88 3.16 1.02 1.80 0.17 0.35 2.63 0.70
Prepaid Expenses		 3.52 4.08 4.01 3.45 1.90 1.30 1.62 2.42 12 5.47 21
Plant, Property, & Equipment, net		 11 11 13 10 6.11 4.03 3.82 3.55 3.75 4.06 4.35
Total Noncurrent Assets		 32 31 175 160 51 52 34 30 31 30 41
Intangible Assets		 22 21 81 68 49 49 31 27 27 27 27
Other Noncurrent Operating Assets		 1.72 1.43 2.13 1.93 1.93 3.51 3.49 3.07 4.11 2.68 14
Total Liabilities & Shareholders' Equity		 248 338 383 316 156 123 236 445 353 466 792
Total Liabilities		 36 47 118 79 32 29 26 25 27 36 45
Total Current Liabilities		 24 30 35 28 13 12 14 17 19 31 40
Accounts Payable		 2.60 1.51 1.74 1.72 1.07 1.17 1.05 1.23 3.34 3.49 3.27
Accrued Expenses		 19 24 29 19 7.01 6.50 8.46 12 13 22 34
Other Current Liabilities		 2.59 4.42 4.83 6.57 4.53 3.97 4.70 3.30 2.44 5.60 2.39
Total Noncurrent Liabilities		 12 17 83 52 19 17 12 8.65 7.92 5.33 5.83
Other Noncurrent Operating Liabilities		 12 17 83 52 19 17 12 8.65 7.92 5.33 5.83
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 212 290 265 236 124 94 209 419 326 429 747
Total Preferred & Common Equity		 212 290 265 236 124 94 209 419 326 429 747
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Common Equity		 212 290 265 236 124 94 209 419 326 429 747
Common Stock		 673 879 982 1,046 1,084 1,105 1,280 1,561 1,581 1,823 2,299
Retained Earnings		 -464 -591 -719 -813 -962 -1,013 -1,073 -1,144 -1,256 -1,397 -1,555
Accumulated Other Comprehensive Income / (Loss)		 2.59 2.31 2.54 2.56 2.58 2.62 2.59 1.89 1.26 3.31 3.31

Quarterly Balance Sheets for Celldex Therapeutics

This table presents Celldex Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 403 369 325 299 280 869 846 823 739
Total Current Assets		 368 335 290 265 246 835 812 779 694
Cash & Equivalents		 28 19 54 28 21 115 43 36 17
Short-Term Investments		 328 305 224 224 214 709 760 720 656
Accounts Receivable		 0.10 0.19 1.31 0.12 0.25 2.67 1.53 0.85 1.06
Prepaid Expenses		 11 11 9.90 12 10 8.81 8.12 22 19
Plant, Property, & Equipment, net		 3.74 3.75 4.00 3.94 4.16 4.06 3.86 4.23 4.60
Total Noncurrent Assets		 31 31 31 31 30 29 30 40 41
Intangible Assets		 27 27 27 27 27 27 27 27 27
Other Noncurrent Operating Assets		 4.05 3.68 3.74 3.36 2.97 2.27 2.56 13 14
Total Liabilities & Shareholders' Equity		 403 369 325 299 280 869 846 823 739
Total Liabilities		 38 24 22 22 34 30 32 37 36
Total Current Liabilities		 30 16 15 16 28 26 28 32 32
Accounts Payable		 0.90 2.27 3.37 0.88 3.59 3.23 3.80 1.11 3.41
Accrued Expenses		 11 11 9.37 12 18 18 19 28 25
Other Current Liabilities		 18 2.59 2.47 2.51 5.78 5.52 5.26 2.78 3.15
Total Noncurrent Liabilities		 7.92 7.52 6.56 6.13 5.70 3.94 4.27 5.18 4.47
Other Noncurrent Operating Liabilities		 7.92 7.52 6.56 6.13 5.70 3.94 4.27 5.18 4.47
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 365 345 303 278 247 839 814 786 703
Total Preferred & Common Equity		 365 345 303 278 247 839 814 786 703
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 365 345 303 278 247 839 814 786 703
Common Stock		 1,568 1,575 1,586 1,591 1,599 2,267 2,278 2,289 2,308
Retained Earnings		 -1,203 -1,229 -1,285 -1,316 -1,354 -1,430 -1,466 -1,508 -1,609
Accumulated Other Comprehensive Income / (Loss)		 -0.42 -0.11 2.12 2.07 2.14 2.24 1.78 5.29 3.57

Annual Metrics And Ratios for Celldex Therapeutics

This table displays calculated financial ratios and metrics derived from Celldex Therapeutics' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -12.77% 52.82% 23.83% 87.78% -25.15% -62.54% 107.61% -37.30% -49.32% 192.02% 1.99%
EBITDA Growth		 -49.01% -5.07% -1.10% 8.18% -32.57% 66.61% -17.23% -18.67% -56.19% -41.49% -31.63%
EBIT Growth		 -50.33% -5.81% -2.61% 8.57% -28.73% 64.82% -15.12% -12.45% -61.75% -34.11% -26.23%
NOPAT Growth		 -50.33% -5.81% -2.61% 8.57% -28.73% 64.82% -15.12% -12.45% -61.75% -34.11% -26.23%
Net Income Growth		 -44.79% -7.72% -1.05% 27.62% -62.51% 66.35% -17.50% -17.95% -59.30% -25.91% -11.62%
EPS Growth		 -29.41% 0.76% -1.05% 27.62% -62.51% 75.76% 42.45% 18.81% -46.34% -21.67% 16.10%
Operating Cash Flow Growth		 -50.05% 2.61% -14.31% 11.59% 24.71% 38.31% 12.95% -50.75% -70.31% -3.43% -47.06%
Free Cash Flow Firm Growth		 -56.91% -0.97% -109.87% 36.87% 59.94% 10.50% 22.26% -55.74% -96.46% -2.00% -65.09%
Invested Capital Growth		 -36.85% -97.97% 34,925.46% 28.14% -69.01% -1.32% -49.62% -24.83% 89.31% -73.78% 289.81%
Revenue Q/Q Growth		 31.40% 6.06% 1.25% 14.17% -15.05% -19.74% 64.15% -42.61% 118.85% 57.69% -29.63%
EBITDA Q/Q Growth		 -7.96% -0.94% -0.43% 6.56% 7.26% -4.44% -20.83% 6.51% -8.12% -15.62% -4.81%
EBIT Q/Q Growth		 -8.83% -1.08% -1.08% 7.13% 7.89% -1.60% -22.87% 5.87% -7.01% -14.65% -4.50%
NOPAT Q/Q Growth		 -8.83% -1.08% -1.08% 7.13% 7.89% -1.60% -22.87% 5.87% -7.01% -14.65% -4.50%
Net Income Q/Q Growth		 -9.01% -0.68% 0.29% 23.43% -3.82% -2.10% -23.70% 2.42% -5.98% -13.50% -2.46%
EPS Q/Q Growth		 -8.20% 2.24% 0.29% 23.43% -3.82% -7.67% -64.23% -3.14% -6.19% -10.19% 5.04%
Operating Cash Flow Q/Q Growth		 -7.70% 7.89% -6.20% 0.82% 5.16% 8.71% 12.53% -18.05% -7.50% -11.16% 0.04%
Free Cash Flow Firm Q/Q Growth		 -7.61% 9.22% -83.37% 31.99% 32.14% 13.07% 22.03% -27.45% -8.35% -10.40% -2.34%
Invested Capital Q/Q Growth		 -30.58% -98.46% 446.48% 23.30% 33.41% 4.15% -50.84% -17.60% -3.16% -50.99% -27.36%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -3,314.61% -2,279.05% -1,860.60% -909.73% -1,611.27% -1,436.13% -810.92% -1,534.81% -4,730.34% -2,291.97% -2,957.98%
Operating Margin		 -3,414.11% -2,363.89% -1,958.68% -953.68% -1,640.13% -1,540.19% -854.06% -1,531.78% -4,889.01% -2,245.27% -2,778.89%
EBIT Margin		 -3,414.11% -2,363.89% -1,958.68% -953.68% -1,640.13% -1,540.19% -854.06% -1,531.78% -4,889.01% -2,245.27% -2,778.89%
Profit (Net Income) Margin		 -3,292.81% -2,321.11% -1,894.05% -730.06% -1,585.07% -1,423.96% -805.88% -1,516.04% -4,765.59% -2,054.76% -2,248.76%
Tax Burden Percent		 100.00% 100.00% 100.00% 79.30% 99.50% 100.00% 98.09% 99.68% 100.00% 100.00% 100.00%
Interest Burden Percent		 96.45% 98.19% 96.70% 96.53% 97.13% 92.45% 96.20% 99.29% 97.48% 91.51% 80.92%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -624.89% -1,674.12% -245.26% -98.58% -172.48% -129.09% -198.97% -381.26% -496.73% -806.56% -1,000.51%
ROIC Less NNEP Spread (ROIC-NNEP)		 -612.05% -1,659.24% -230.46% -93.74% -136.77% -113.49% -187.04% -374.41% -487.85% -797.43% -996.80%
Return on Net Nonoperating Assets (RNNOA)		 580.46% 1,623.42% 198.99% 61.50% 88.59% 82.43% 159.56% 358.83% 466.60% 769.11% 973.67%
Return on Equity (ROE)		 -44.44% -50.70% -46.27% -37.08% -83.89% -46.66% -39.41% -22.43% -30.13% -37.45% -26.84%
Cash Return on Invested Capital (CROIC)		 -579.72% -1,482.10% -444.12% -123.24% -67.10% -127.77% -132.98% -352.90% -558.47% -689.66% -1,118.85%
Operating Return on Assets (OROA)		 -41.15% -44.24% -36.87% -34.77% -66.37% -39.49% -35.32% -20.94% -28.90% -37.77% -31.01%
Return on Assets (ROA)		 -39.68% -43.44% -35.66% -26.62% -64.14% -36.51% -33.32% -20.72% -28.17% -34.56% -25.10%
Return on Common Equity (ROCE)		 -44.44% -50.70% -46.27% -37.08% -83.89% -46.66% -39.41% -22.43% -30.13% -37.45% -26.84%
Return on Equity Simple (ROE_SIMPLE)		 -55.79% -43.85% -48.42% -39.36% -121.86% -54.11% -28.55% -16.81% -34.43% -32.95% -21.13%
Net Operating Profit after Tax (NOPAT)		 -86 -91 -93 -85 -110 -39 -44 -50 -81 -108 -137
NOPAT Margin		 -2,389.88% -1,654.72% -1,371.08% -667.57% -1,148.09% -1,078.13% -597.84% -1,072.24% -3,422.31% -1,571.69% -1,945.22%
Net Nonoperating Expense Percent (NNEP)		 -12.85% -14.88% -14.80% -4.84% -35.71% -15.60% -11.93% -6.85% -8.88% -9.13% -3.71%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -24.73% -25.21% -18.28%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 575.07% 617.46% 530.19% 196.21% 202.02% 431.74% 194.88% 440.51% 1,153.80% 449.14% 549.12%
R&D to Revenue		 2,910.79% 1,827.94% 1,513.79% 754.70% 696.68% 1,194.29% 573.39% 1,146.23% 3,489.94% 1,714.53% 2,329.77%
Operating Expenses to Revenue		 3,514.11% 2,463.89% 2,058.68% 1,053.68% 1,740.13% 1,640.19% 954.06% 1,631.78% 4,989.01% 2,345.27% 2,878.89%
Earnings before Interest and Taxes (EBIT)		 -122 -130 -133 -122 -156 -55 -63 -71 -115 -155 -195
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -119 -125 -126 -116 -154 -51 -60 -71 -111 -158 -208
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 7.72 5.33 1.35 1.63 0.28 0.38 3.31 4.30 6.44 4.37 2.24
Price to Tangible Book Value (P/TBV)		 9.04 5.94 3.86 4.96 0.45 0.79 3.88 4.60 7.02 4.66 2.33
Price to Revenue (P/Rev)		 455.94 282.26 52.82 30.31 3.58 10.07 93.45 387.68 890.64 272.34 238.82
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 135.06 5,818.87 2.23 2.55 0.00 0.00 33.40 124.25 84.43 260.34 43.79
Enterprise Value to Revenue (EV/Rev)		 399.88 229.36 24.85 19.37 0.00 0.00 67.24 299.90 761.26 210.79 135.50
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.95 -0.98 -0.86 -0.66 -0.65 -0.73 -0.85 -0.96 -0.96 -0.96 -0.98
Leverage Ratio		 1.12 1.17 1.30 1.39 1.31 1.28 1.18 1.08 1.07 1.08 1.07
Compound Leverage Factor		 1.08 1.15 1.25 1.34 1.27 1.18 1.14 1.07 1.04 0.99 0.87
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 23.63 16.79 -1.43 -1.47 -10.59 -11.70 9.42 39.91 42.44 26.60 19.71
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.37 9.75 5.55 5.22 7.86 5.73 13.93 24.86 17.07 13.87 18.91
Quick Ratio		 8.23 9.62 5.44 5.09 7.71 5.62 13.81 24.71 16.41 13.69 18.38
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -80 -80 -168 -106 -43 -38 -30 -46 -91 -93 -153
Operating Cash Flow to CapEx		 -5,263.71% -2,028.04% -4,108.91% -5,588.98% -15,973.46% -6,528.13% -2,699.00% -4,984.37% -5,897.21% -5,901.60% -8,221.89%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.02 0.02 0.04 0.04 0.03 0.04 0.01 0.01 0.02 0.01
Accounts Receivable Turnover		 7.83 7.85 4.93 6.96 3.78 1.71 5.27 4.71 9.08 4.63 4.22
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.35 0.50 0.55 1.08 1.16 0.70 1.89 1.26 0.65 1.76 1.67
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 46.62 46.52 74.07 52.47 96.47 213.35 69.30 77.46 40.19 78.88 86.52
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 46.62 46.52 74.07 52.47 96.47 213.35 69.30 77.46 40.19 78.88 86.52
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 11 0.22 76 97 30 30 15 11 21 5.57 22
Invested Capital Turnover		 0.26 1.01 0.18 0.15 0.15 0.12 0.33 0.36 0.15 0.51 0.51
Increase / (Decrease) in Invested Capital		 -6.20 -10 75 21 -67 -0.40 -15 -3.71 10 -16 16
Enterprise Value (EV)		 1,434 1,257 169 247 -60 -28 499 1,395 1,794 1,451 951
Market Capitalization		 1,635 1,547 358 386 34 36 693 1,803 2,099 1,874 1,677
Book Value per Share		 $2.36 $2.94 $2.62 $1.74 $0.72 $5.83 $5.29 $8.99 $6.93 $9.08 $11.26
Tangible Book Value per Share		 $2.02 $2.64 $0.92 $0.57 $0.44 $2.81 $4.52 $8.41 $6.35 $8.51 $10.85
Total Capital		 212 290 265 236 124 94 209 419 326 429 747
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -201 -290 -190 -139 -94 -64 -194 -408 -305 -424 -725
Capital Expenditures (CapEx)		 1.93 4.88 2.75 1.79 0.47 0.71 1.50 1.22 1.76 1.82 1.92
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -21 -25 -29 -22 -7.55 -9.33 -11 -14 -5.87 -23 -18
Debt-free Net Working Capital (DFNWC)		 180 265 160 117 86 55 184 394 299 401 708
Net Working Capital (NWC)		 180 265 160 117 86 55 184 394 299 401 708
Net Nonoperating Expense (NNE)		 32 37 35 7.96 42 12 15 21 32 33 21
Net Nonoperating Obligations (NNO)		 -201 -290 -190 -139 -94 -64 -194 -408 -305 -424 -725
Total Depreciation and Amortization (D&A)		 3.57 4.65 6.66 5.60 2.75 3.72 3.20 -0.14 3.74 -3.21 -13
Debt-free, Cash-free Net Working Capital to Revenue		 -573.03% -459.73% -433.69% -175.84% -79.10% -261.07% -145.39% -299.70% -249.00% -334.59% -251.04%
Debt-free Net Working Capital to Revenue		 5,033.30% 4,830.22% 2,362.89% 918.31% 906.66% 1,540.86% 2,475.56% 8,477.98% 12,689.14% 5,819.67% 10,080.60%
Net Working Capital to Revenue		 5,033.30% 4,830.22% 2,362.89% 918.31% 906.66% 1,540.86% 2,475.56% 8,477.98% 12,689.14% 5,819.67% 10,080.60%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($19.80) ($19.65) ($19.05) ($10.80) ($14.48) ($3.51) ($2.02) ($1.64) ($2.40) ($2.92) ($2.45)
Adjusted Weighted Average Basic Shares Outstanding		 5.97M 6.58M 8.21M 9.40M 12.44M 17.57M 39.61M 42.87M 46.89M 48.45M 64.40M
Adjusted Diluted Earnings per Share		 ($19.80) ($19.65) ($19.05) ($10.80) ($14.48) ($3.51) ($2.02) ($1.64) ($2.40) ($2.92) ($2.45)
Adjusted Weighted Average Diluted Shares Outstanding		 5.97M 6.58M 8.21M 9.40M 12.44M 17.57M 39.61M 42.87M 46.89M 48.45M 64.40M
Adjusted Basic & Diluted Earnings per Share		 ($19.80) ($19.65) ($19.05) ($10.80) ($14.48) ($3.51) ($2.02) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.96M 6.47M 6.77M 8.57M 10.44M 14.51M 29.64M 46.74M 47.21M 55.90M 66.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -86 -91 -93 -76 -33 -37 -32 -47 -70 -99 -137
Normalized NOPAT Margin		 -2,389.88% -1,654.72% -1,371.08% -596.16% -343.34% -1,042.87% -427.98% -1,019.57% -2,976.83% -1,444.56% -1,945.22%
Pre Tax Income Margin		 -3,292.81% -2,321.11% -1,894.05% -920.61% -1,593.09% -1,423.96% -821.61% -1,520.92% -4,765.59% -2,054.76% -2,248.76%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Celldex Therapeutics

This table displays calculated financial ratios and metrics derived from Celldex Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 166.01% 384.38% 455.75% 64.42% 272.73% 156.11% -83.87% 832.09% 110.35% -71.56% 345.51%
EBITDA Growth		 -15.71% -43.22% -52.26% 4.30% -56.11% -76.85% -30.74% -49.54% -32.24% -19.42% -48.66%
EBIT Growth		 -33.00% -37.09% -39.62% 8.77% -48.90% -70.80% -25.06% -39.49% -26.40% -17.64% -54.50%
NOPAT Growth		 -33.00% -37.09% -39.62% 8.77% -48.90% -70.80% -25.06% -39.49% -26.40% -17.64% -54.50%
Net Income Growth		 -30.96% -31.46% -27.38% 15.28% -42.85% -63.50% -11.74% -17.51% -10.09% -8.74% -63.97%
EPS Growth		 -26.67% -32.56% -26.53% 15.58% -42.11% -47.37% 9.68% 16.92% 20.99% 15.48% -44.64%
Operating Cash Flow Growth		 -114.95% -49.85% -16.45% -22.26% 46.03% -49.49% -42.25% -7.84% -191.35% 0.18% -33.80%
Free Cash Flow Firm Growth		 -1,370.36% -180.61% -86.04% -156.69% 33.98% 40.23% 36.03% 52.46% -200.81% -213.53% -212.32%
Invested Capital Growth		 61.09% 89.31% 38.11% 200.15% -48.19% -73.78% -39.36% -54.34% 163.03% 289.81% 101.06%
Revenue Q/Q Growth		 149.69% 296.31% -40.05% -72.29% 466.04% 172.31% -96.22% 1,501.28% 27.74% -63.18% -40.85%
EBITDA Q/Q Growth		 23.21% -2.84% -18.99% -1.84% -25.26% -16.50% 12.03% -16.49% -10.77% -5.21% -9.51%
EBIT Q/Q Growth		 23.90% -0.68% -16.45% -2.26% -24.20% -15.49% 14.74% -14.06% -12.54% -7.48% -11.98%
NOPAT Q/Q Growth		 23.90% -0.68% -16.45% -2.26% -24.20% -15.49% 14.74% -14.06% -12.54% -7.48% -11.98%
Net Income Q/Q Growth		 25.61% 1.11% -10.85% -3.89% -25.43% -13.19% 24.24% -9.25% -17.52% -11.80% -14.24%
EPS Q/Q Growth		 25.97% 0.00% -8.77% -4.84% -24.62% -3.70% 33.33% 3.57% -18.52% -10.94% -14.08%
Operating Cash Flow Q/Q Growth		 -58.21% 38.16% -31.28% 4.81% 30.16% -71.29% -24.91% 27.83% -88.69% 41.31% -67.42%
Free Cash Flow Firm Q/Q Growth		 -78.67% -6.63% 0.32% -35.17% 54.05% 3.46% -6.68% -0.45% -190.77% -0.63% -6.27%
Invested Capital Q/Q Growth		 165.16% -3.16% 14.59% 2.00% -54.23% -50.99% 164.97% -23.19% 163.67% -27.36% 36.67%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -6,625.80% -1,719.40% -3,412.72% -12,540.67% -2,775.15% -1,187.29% -27,657.69% -2,012.01% -1,744.69% -4,984.77% -9,228.63%
Operating Margin		 -6,804.91% -1,728.77% -3,357.91% -12,389.93% -2,718.46% -1,152.92% -26,030.77% -1,854.16% -1,633.53% -4,768.26% -9,027.19%
EBIT Margin		 -6,804.91% -1,728.77% -3,357.91% -12,389.93% -2,718.46% -1,152.92% -26,030.77% -1,854.16% -1,633.53% -4,768.26% -9,027.19%
Profit (Net Income) Margin		 -6,580.84% -1,642.10% -3,036.30% -11,381.34% -2,522.08% -1,048.32% -21,030.77% -1,434.83% -1,319.99% -4,007.83% -7,740.43%
Tax Burden Percent		 100.00% 30.96% 0.00% 0.00% 0.00% 30.62% 100.00% 0.00% 0.00% 29.83% 100.00%
Interest Burden Percent		 96.71% 306.76% 0.00% 0.00% 0.00% 296.95% 80.79% 0.00% 0.00% 281.76% 85.75%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -288.47% -175.64% -352.70% -1,704.94% -498.65% -414.16% -5,656.50% -595.62% -552.73% -1,716.76% -2,148.84%
ROIC Less NNEP Spread (ROIC-NNEP)		 -286.49% -173.69% -350.69% -1,702.56% -495.29% -411.42% -5,655.71% -594.97% -551.60% -1,715.39% -2,147.53%
Return on Net Nonoperating Assets (RNNOA)		 273.46% 166.13% 329.68% 1,614.82% 467.42% 396.81% 5,461.86% 575.24% 529.55% 1,675.58% 2,085.59%
Return on Equity (ROE)		 -15.01% -9.52% -23.02% -90.12% -31.23% -17.35% -194.65% -20.38% -23.18% -41.18% -63.25%
Cash Return on Invested Capital (CROIC)		 -470.67% -558.47% -446.98% -612.66% -502.99% -689.66% -533.18% -605.58% -722.99% -1,118.85% -751.15%
Operating Return on Assets (OROA)		 -17.67% -10.22% -28.26% -114.85% -36.54% -19.39% -264.90% -26.89% -29.54% -53.22% -84.85%
Return on Assets (ROA)		 -17.09% -9.71% -25.55% -105.50% -33.90% -17.63% -214.01% -20.81% -23.87% -44.73% -72.76%
Return on Common Equity (ROCE)		 -15.01% -9.52% -23.02% -90.12% -31.23% -17.35% -194.65% -20.38% -23.18% -41.18% -63.25%
Return on Equity Simple (ROE_SIMPLE)		 -30.68% 0.00% -39.19% -40.76% -50.51% 0.00% -17.28% -18.46% -19.61% 0.00% -25.44%
Net Operating Profit after Tax (NOPAT)		 -19 -20 -23 -23 -29 -33 -28 -32 -36 -39 -44
NOPAT Margin		 -4,763.44% -1,210.14% -2,350.54% -8,672.95% -1,902.92% -807.04% -18,221.54% -1,297.91% -1,143.47% -3,337.78% -6,319.04%
Net Nonoperating Expense Percent (NNEP)		 -1.98% -1.95% -2.01% -2.38% -3.36% -2.74% -0.80% -0.65% -1.14% -1.37% -1.32%
Return On Investment Capital (ROIC_SIMPLE)		 - -5.98% - - - -7.77% -3.39% - - -5.25% -6.25%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 1,604.67% 409.11% 686.66% 2,694.40% 541.92% 213.80% 5,835.26% 365.41% 315.07% 873.45% 1,556.83%
R&D to Revenue		 5,300.25% 1,419.65% 2,771.25% 9,795.52% 2,276.53% 736.53% 20,295.51% 1,588.75% 1,418.46% 3,994.81% 7,570.36%
Operating Expenses to Revenue		 6,904.91% 1,828.77% 3,457.91% 12,489.93% 2,818.46% 1,252.92% 26,130.77% 1,954.16% 1,733.53% 4,868.26% 9,127.19%
Earnings before Interest and Taxes (EBIT)		 -28 -28 -32 -33 -41 -48 -41 -46 -52 -56 -63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -27 -28 -33 -34 -42 -49 -43 -50 -56 -59 -64
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.81 6.44 5.61 5.78 5.27 4.37 2.37 3.00 2.87 2.24 1.71
Price to Tangible Book Value (P/TBV)		 4.13 7.02 6.16 6.40 5.92 4.66 2.44 3.10 2.97 2.33 1.78
Price to Revenue (P/Rev)		 1,220.77 890.64 539.21 492.56 297.97 272.34 326.69 293.83 225.85 238.82 159.39
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 45.17 84.43 58.31 54.37 93.69 260.34 78.54 144.33 50.06 43.79 17.90
Enterprise Value to Revenue (EV/Rev)		 920.43 761.26 450.83 414.92 244.05 210.79 191.01 197.19 150.07 135.50 70.32
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.95 -0.96 -0.94 -0.95 -0.94 -0.96 -0.97 -0.97 -0.96 -0.98 -0.97
Leverage Ratio		 1.06 1.07 1.07 1.09 1.10 1.08 1.05 1.05 1.07 1.07 1.04
Compound Leverage Factor		 1.03 3.28 0.00 0.00 0.00 3.22 0.84 0.00 0.00 3.01 0.89
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 29.26 43.25 41.94 38.67 16.97 27.36 38.03 44.36 34.60 20.29 17.57
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 20.54 17.07 19.03 16.93 8.84 13.87 31.77 29.36 24.27 18.91 21.67
Quick Ratio		 19.87 16.41 18.38 16.16 8.46 13.69 31.44 29.06 23.58 18.38 21.06
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -28 -30 -29 -40 -18 -18 -19 -19 -55 -55 -59
Operating Cash Flow to CapEx		 -10,200.58% -9,260.43% -4,883.59% -6,633.17% -12,097.45% -4,884.83% -11,813.37% -10,703.28% -10,153.58% -4,295.77% -20,517.74%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01
Accounts Receivable Turnover		 5.58 9.08 4.05 30.28 19.80 4.63 3.05 10.05 18.07 4.22 4.05
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.30 0.65 0.84 0.85 1.10 1.76 1.51 2.13 2.38 1.67 1.75
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 65.41 40.19 90.21 12.05 18.44 78.88 119.77 36.32 20.20 86.52 90.18
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 65.41 40.19 90.21 12.05 18.44 78.88 119.77 36.32 20.20 86.52 90.18
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 22 21 24 25 11 5.57 15 11 30 22 30
Invested Capital Turnover		 0.06 0.15 0.15 0.20 0.26 0.51 0.31 0.46 0.48 0.51 0.34
Increase / (Decrease) in Invested Capital		 8.32 10 6.72 17 -11 -16 -9.59 -13 19 16 15
Enterprise Value (EV)		 991 1,794 1,420 1,351 1,065 1,451 1,160 1,637 1,497 951 532
Market Capitalization		 1,315 2,099 1,699 1,603 1,301 1,874 1,984 2,439 2,253 1,677 1,205
Book Value per Share		 $7.39 $6.93 $6.41 $5.87 $5.22 $9.08 $14.24 $12.34 $11.86 $11.26 $10.59
Tangible Book Value per Share		 $6.80 $6.35 $5.84 $5.30 $4.65 $8.51 $13.78 $11.93 $11.45 $10.85 $10.18
Total Capital		 345 326 303 278 247 429 839 814 786 747 703
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -323 -305 -278 -253 -235 -424 -824 -802 -756 -725 -673
Capital Expenditures (CapEx)		 0.35 0.24 0.59 0.41 0.16 0.67 0.34 0.27 0.55 0.76 0.27
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.16 -5.87 -4.01 -3.52 -17 -23 -15 -18 -9.25 -18 -12
Debt-free Net Working Capital (DFNWC)		 318 299 274 249 218 401 809 784 747 708 662
Net Working Capital (NWC)		 318 299 274 249 218 401 809 784 747 708 662
Net Nonoperating Expense (NNE)		 7.40 6.97 6.63 7.26 9.39 9.97 4.38 3.42 5.63 7.87 9.88
Net Nonoperating Obligations (NNO)		 -323 -305 -278 -253 -235 -424 -824 -802 -756 -725 -673
Total Depreciation and Amortization (D&A)		 0.73 0.15 -0.53 -0.40 -0.86 -1.42 -2.54 -3.94 -3.55 -2.54 -1.40
Debt-free, Cash-free Net Working Capital to Revenue		 -479.02% -249.00% -127.27% -108.23% -395.21% -334.59% -243.96% -216.82% -92.72% -251.04% -152.82%
Debt-free Net Working Capital to Revenue		 29,555.43% 12,689.14% 8,710.41% 7,655.12% 4,996.49% 5,819.67% 13,324.00% 9,447.33% 7,485.46% 10,080.60% 8,754.32%
Net Working Capital to Revenue		 29,555.43% 12,689.14% 8,710.41% 7,655.12% 4,996.49% 5,819.67% 13,324.00% 9,447.33% 7,485.46% 10,080.60% 8,754.32%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.57) ($0.57) ($0.62) ($0.65) ($0.81) ($0.84) ($0.56) ($0.54) ($0.64) ($0.71) ($0.81)
Adjusted Weighted Average Basic Shares Outstanding		 46.92M 46.89M 47.21M 47.25M 47.26M 48.45M 58.87M 66.02M 66.29M 64.40M 66.38M
Adjusted Diluted Earnings per Share		 ($0.57) ($0.57) ($0.62) ($0.65) ($0.81) ($0.84) ($0.56) ($0.54) ($0.64) ($0.71) ($0.81)
Adjusted Weighted Average Diluted Shares Outstanding		 46.92M 46.89M 47.21M 47.25M 47.26M 48.45M 58.87M 66.02M 66.29M 64.40M 66.38M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 47.10M 47.21M 47.25M 47.26M 47.26M 55.90M 65.91M 66.29M 66.34M 66.38M 66.39M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -20 -23 -23 -29 -33 -28 -32 -36 -39 -44
Normalized NOPAT Margin		 -4,763.44% -1,210.14% -2,350.54% -8,672.95% -1,902.92% -807.04% -18,221.54% -1,297.91% -1,143.47% -3,337.78% -6,319.04%
Pre Tax Income Margin		 -6,580.84% -5,303.22% 0.00% 0.00% 0.00% -3,423.60% -21,030.77% 0.00% 0.00% -13,435.15% -7,740.43%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Celldex Therapeutics (NASDAQ: CLDX) continues to operate with no reported cost of revenue across all recent quarters, suggesting their gross profit equals total revenue, though this revenue is quite low compared to expenses.

Positive factors in Celldex’s latest financials and trends:

  • As of Q1 2025, Celldex holds a very large amount in short-term investments ($656.2 million), providing strong liquidity.
  • The company consistently generates significant interest and investment income, with $8.9 million in Q1 2025, contributing positively to other income.
  • Cash and equivalents remain substantial over quarters, with about $17.1 million in Q1 2025.
  • Despite negative net income, Celldex is able to raise capital via equity issuances periodically, with $202,000 received in Q1 2025 financing activities.

Neutral observations:

  • Operating revenue is very low relative to operating expenses each quarter, indicating that Celldex is primarily in a development or early commercialization stage typical for biotech firms.
  • Research & development expenses have increased substantially over the last three years, reaching $52.6 million in Q1 2025, reflecting ongoing investment in pipeline development.
  • Selling, general & administrative expenses remain high, approximately $10.8 million in Q1 2025, but relatively flat compared to recent quarters.
  • Total liabilities have remained stable between $30 million to $37 million over the past year, a manageable level compared to equity.
  • Weighted average diluted shares outstanding slightly increased over time, from about 46-47 million shares in 2022 to approximately 66 million shares in early 2025, suggesting moderate dilution from equity financing.

Negative aspects and risks:

  • Celldex has continued to report significant net losses each quarter, with Q1 2025 net loss of $53.8 million, and no signs of profitability forthcoming given the trend.
  • Operating expenses, driven by heavy R&D spend, are substantially exceeding operating revenue by a wide margin (e.g., $69.5K revenue vs. $63.4 million expenses in Q1 2025).
  • Negative cash flow from operating activities is considerable, with Q1 2025 showing an outflow of approximately $54.4 million, necessitating external financing to sustain operations.
  • Equity shareholders' retained earnings are deeply negative (around -$1.6 billion as of Q1 2025), reflecting accumulated losses over time.
  • Basic and diluted EPS remain negative each quarter, currently at -$0.81 per share in Q1 2025, reflecting ongoing unprofitability.

Summary: Celldex Therapeutics is a financially typical biotech company still heavily investing in research and development with high ongoing losses and negative operating cash flow. It maintains strong liquidity through substantial short-term investments and periodic equity raises. The company’s revenues remain minimal while expenses are high, indicating continuing need for external funding. Investors should be aware of the risk profile of such a development-stage biotech, including dilution and ongoing substantial losses, while recognizing the significant cash reserves as a buffer for continued operations.

08/09/25 03:58 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Celldex Therapeutics' Financials

When does Celldex Therapeutics' financial year end?

According to the most recent income statement we have on file, Celldex Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Celldex Therapeutics' net income changed over the last 10 years?

Celldex Therapeutics' net income were at -$157.86 million at the end of 2024, a 11.6% increase from 2023, and a 33.7% increase since 2014. View Celldex Therapeutics' forecast to see where analysts expect Celldex Therapeutics to go next.

What is Celldex Therapeutics' operating income?
Celldex Therapeutics' total operating income in 2024 was -$195.08 million, based on the following breakdown:
  • Total Gross Profit: $7.02 million
  • Total Operating Expenses: $202.10 million
How has Celldex Therapeutics' revenue changed over the last 10 years?

Over the last 10 years, Celldex Therapeutics' total revenue changed from $3.59 million in 2014 to $7.02 million in 2024, a change of 95.8%.

How much debt does Celldex Therapeutics have?

Celldex Therapeutics' total liabilities were at $45.34 million at the end of 2024, a 24.4% increase from 2023, and a 24.7% increase since 2014.

How much cash does Celldex Therapeutics have?

In the past 10 years, Celldex Therapeutics' cash and equivalents has ranged from $11.23 million in 2019 to $72.11 million in 2015, and is currently $28.36 million as of their latest financial filing in 2024.

How has Celldex Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Celldex Therapeutics' book value per share changed from 2.36 in 2014 to 11.26 in 2024, a change of 376.6%.


Related Companies

This page (NASDAQ:CLDX) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsored
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsored
Man Who Called Nvidia at $1.10 Says Buy This Now...
In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...
The Oxford Club | Sponsored
Crypto Income (almost instantly)
How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...
Awesomely, LLC | Sponsored
One stock to replace Nvidia
I'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...
InvestorPlace | Sponsored
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
Crypto bros: Meet your replacement
Larry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...
Brownstone Research | Sponsored
Utah’s New Oil Find
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...
Stansberry Research | Sponsored